Biopsy type does not affect the number of stages during Mohs micrographic surgery: a retrospective study

Clin Exp Dermatol. 2023 Jun 5;48(6):674-675. doi: 10.1093/ced/llad050.

Abstract

Mohs micrographic surgery (MMS) is the treatment of choice for high-risk basal cell carcinoma (BCC). However, there are no evidence-based recommendations regarding which biopsy type is more appropriate to obtain tumour samples prior to MMS. Shave or punch biopsies are performed depending on the clinical characteristics of the tumour, surgeon experience and local protocols. However, biopsy type might result in difficult histopathological interpretation and influence the practical implementation of MMS. We performed a retrospective study on 208 consecutive BCCs treated with MMS. Of the 208 BCC biopsies, 42 (20.2%) were obtained by the shave method and 166 (79.8%) via punch. Those obtained with the shave technique had a mean of 1.64 stages vs. 1.69 stages with the punch technique (P = 0.130). These findings suggest biopsy type does not affect Mohs surgery performance. The biopsy type of choice is the one deemed adequate for each specific case to obtain a diagnosis and tumour subtyping.

MeSH terms

  • Biopsy
  • Carcinoma, Basal Cell* / pathology
  • Carcinoma, Basal Cell* / surgery
  • Humans
  • Mohs Surgery / methods
  • Neoplasm Recurrence, Local / pathology
  • Retrospective Studies
  • Skin Neoplasms* / pathology
  • Skin Neoplasms* / surgery